BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 27765925)

  • 1. Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm.
    Park CK; Park JS; Kim HS; Rha SY; Hyung WJ; Cheong JH; Noh SH; Lee SK; Lee YC; Huh YM; Kim H
    Oncotarget; 2016 Nov; 7(44):72099-72112. PubMed ID: 27765925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
    Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
    Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus positivity, not mismatch repair-deficiency, is a favorable risk factor for lymph node metastasis in submucosa-invasive early gastric cancer.
    Park JH; Kim EK; Kim YH; Kim JH; Bae YS; Lee YC; Cheong JH; Noh SH; Kim H
    Gastric Cancer; 2016 Oct; 19(4):1041-1051. PubMed ID: 26573601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Integrative Morphomolecular Classification System of Gastric Carcinoma With Distinct Clinical Outcomes.
    Tsai JH; Jeng YM; Chen KH; Lee CH; Yuan CT; Liau JY
    Am J Surg Pathol; 2020 Aug; 44(8):1017-1030. PubMed ID: 32568823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients].
    Liu Y; Zang FL; Qiu ZQ; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Liang H; Sun Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):440-448. PubMed ID: 34000774
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mismatch repair deficiency screening in colorectal carcinoma by a four-antibody immunohistochemical panel in Pakistani population and its correlation with histopathological parameters.
    Hashmi AA; Ali R; Hussain ZF; Faridi N; Khan EY; Bakar SMA; Edhi MM; Khan M
    World J Surg Oncol; 2017 Jun; 15(1):116. PubMed ID: 28651545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
    Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
    Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.
    Lee MJ; Kim N; Choung HK; Choe JY; Khwarg SI; Kim JE
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):125-33. PubMed ID: 26141290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
    Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
    World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of EGFR and ERBB2 (HER2) in Gastric and Gastroesophageal Carcinomas: EGFR Amplification is Associated With a Worse Prognosis in Early Stage and Well to Moderately Differentiated Carcinoma.
    Liao JB; Lee HP; Fu HT; Lee HS
    Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):374-382. PubMed ID: 27753660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy.
    Kim HS; Shin SJ; Beom SH; Jung M; Choi YY; Son T; Kim HI; Cheong JH; Hyung WJ; Noh SH; Chung H; Park JC; Shin SK; Lee SK; Lee YC; Koom WS; Lim JS; Chung HC; Rha SY; Kim H
    Oncotarget; 2016 Jul; 7(28):44608-44620. PubMed ID: 27331626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are Immunohistochemical Markers Useful in Phenotypic Gastric Cancer Classification?
    Di Pinto F; Armentano R; Arborea G; Schena N; Donghia R; Valentini AM
    Oncology; 2020; 98(8):566-574. PubMed ID: 32316005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases.
    Cappellesso R; Fassan M; Hanspeter E; Bornschein J; d'Amore ES; Cuorvo LV; Mazzoleni G; Barbareschi M; Pizzi M; Guzzardo V; Malfertheiner P; Micev M; Guido M; Giacomelli L; Tsukanov VV; Zagonel V; Nitti D; Rugge M
    Hum Pathol; 2015 May; 46(5):665-72. PubMed ID: 25800719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
    Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
    Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages.
    Cho J; Jeong J; Sung J; Sung CO; Kim KM; Park CK; Choi MG; Sohn TS; Bae JM; Kim S
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S477-84. PubMed ID: 23274580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemistry as a surrogate for molecular subtyping of gastric adenocarcinoma.
    Gonzalez RS; Messing S; Tu X; McMahon LA; Whitney-Miller CL
    Hum Pathol; 2016 Oct; 56():16-21. PubMed ID: 27342907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.